Combined oral prolonged-release oxycodone and naloxone in chronic pain management

Expert Opinion on Investigational Drugs

Volumn 22, Issue 1, 2013, Pages 161-166

  Mercadante, Sebastiano ^a   Giarratano, Antonello ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cancer pain; Chronic pain; Opioid antagonist; Opioids; Oxycodone naloxone combination

Indexed keywords

MORPHINE; NALOXONE; OXYCODONE; PLACEBO;

ABDOMINAL PAIN; ANALGESIA; CHEMISTRY; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG RELEASE; DRUG SAFETY; DYSPEPSIA; HUMAN; NAUSEA; OPIOID INDUCED CONSTIPATION; PHARMACODYNAMICS; REVIEW; TABLET FORMULATION; TREATMENT OUTCOME; VOMITING;

ANALGESICS, OPIOID; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; HUMANS; NALOXONE; OXYCODONE; TREATMENT OUTCOME;

EID: 84870993589     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.752460     Document Type: Review

References (25)

1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
2. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009;5:145-51
3. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
4. Mercadante S. Emerging drugs for cancer-related pain. Support Care Cancer 2011;19:1887-93
5. Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105-9
6. Smith K, Hopp M, Mundin G, et al. Single and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist-antagonist prolonged-release combination in healthy adult volunteers. Clin Ther 2008;30:2051-68
7. Smith K, Hopp M, Mundin G, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011;20:427-39
8. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomized controlled study with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
9. Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 2008;62:1159-67
10. Riley J, Eisenberg E, Muller-Schwefe G, et al. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 2008;24:175-92
11. Van Dorp EL, Yassen A, Dahan A. Naloxone treatment in opioidaddiction: the risks and benefits. Expert Opin Drug Saf 2007;6:125-32
12. Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004;32:447-54
13. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7
14. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
15. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
16. Lowenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43
17. Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Pall Med 2012;26:50-60
18. Lowenstein O, Leyendecker P, Lux EA et al. Efficacy and safety of combined prolonged release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12
19. Schutter U, Frunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377-87
20. Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone-naloxone in the treatment of neuropathic pain-results from a large observational study. Expert Opin Pharmacother 2012;13:299-311
21. Sandner-Kiesling A, Leydendecker F, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:763-74
22. Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract 2011;65:472-8
23. Ricerca IMS Health-Patients on Drug Targin-metodo LRX (Longitudinal Prescription) 2012 Clemens KE, Mikus G. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert Opin Pharmacother 2010;11:297-310
24. Dunlop W, Uhl R, Khan I, et al. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012;15:564-75
25. Mercadante S, Ferrera P, David F, Casuccio A. The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care 2011;28:242-4